Category Archives: Healthcare Products

IQ Biozoom, a medtech startup, develops non-invasive home diagnostics to measure biomarker levels in saliva with unmatched accuracy

WARSAW, 13-Nov-2023 — /EPR HEALTHCARE NEWS/ — IQ Biozoom, a medical technology startup focusing on developing non-invasive home diagnostics, is set to make non-invasive home testing more convenient with their innovative technology that allows for the possibility to measure the concentration of biochemical substances in liquid analytes such as saliva, sweat, urine or tears. More people around the world will be empowered to monitor the course of various diseases from the comfort of their own home with laboratory precision using saliva analysis. Currently,  non-invasive home tests measuring glucose and lactate levels in saliva and, in the near future, hormones or CRP proteins, are being developed as part of the technology development.

IQ Biozoom’s technology includes a sophisticated biosensor system that integrates inkjet printing technology with advanced semiconductors, specifically thin-film transistors. Although not yet in commercial use, it allows the concentration of a selected biomarker to be determined based on contact between a disposable test strip and a body fluid such as saliva. According to analyses, when measuring glucose concentration in saliva, IQ Biozoom’s cutting-edge technology is up to ten times more accurate than current market standards. This means that even very low concentrations of selected biomarkers in the analyte can be determined with laboratory precision. This can be particularly relevant in those cases where the physiological concentration of a selected substance is very low, or where the mere presence of a biomarker in an analyte is indicative of a health disorder.

Most current blood glucose meters need a finger prick which is usually uncomfortable for patients. IQ Biozoom’s technology enables biomarker levels to be tested with laboratory precision based on saliva analysis, making it a completely non-invasive and painless method.

The solution will enable people with, for example, metabolic and endocrine disorders, to monitor their health and manage their disease, as well as take appropriate preventive care. The devices being developed based on IQ Biozoom’s technology are intended to be used for self-contained, non-invasive home diagnostics, allowing for precise laboratory-standard results.

Monitoring biomarkers and analysing their data retrospectively can help to select the right therapy for a patient. By monitoring biomarkers before, during and after therapy, it is possible to assess whether a patient is responding to treatment. If biomarker levels improve, this may indicate that the therapies are working. If there is no improvement, the therapy may need to be changed. Retrospective analysis of biomarker data can help to personalise therapy, tailoring it to the individual patient. The technology also has applications in personalised sports medicine, particularly in the context of physical performance assessment, training planning and training unit selection. Different athletes may have different lactate threshold which means their training plans should be tailored to their individual body characteristics. Testing lactate levels allows for precise individualisation of training.

Currently, invasive glucometers are the devices of choice for glucose level monitoring. According to the Polish Family with Diabetes report, published by the Association for Diabetes Education SED – 84% of people with type 1 diabetes would prefer to use non-invasive glucose monitoring methods, while 60% skip part of their daily testing due to the need for fingertip pricks. In addition to the discomfort felt, the disruption of the skin increases the risk of an infection. In 2021, IQ Biozoom started developing their innovative technology to non-invasively monitor glucose and lactate levels. Other biomarkers such as cortisol or CRP proteins in the body are in the R&D pipeline.

In the third quarter of 2023, IQ Biozoom obtained funding from the VC Link fund, which supports Polish companies developing breakthrough technologies with global potential. But the seed round is not closed yet with the startup seeking further investment to implement the technology and go to market.

The company expects an even faster growth rate in the near future. The home diagnostics market is growing at 5.6% year-to-year and is expected to exceed $13.6 million by 2033, according to FutureMarketInsight.com.

About IQ BIOZOOM

IQ BIOZOOM Ltd (https://iqbiozoom.com/) develops technology for non-invasive home diagnostics. The company is working on innovative devices for measuring the concentration of biochemical substances in saliva: glucose, lactates, and hormones, to enable people with metabolic and endocrine disorders to monitor their health and manage their disease, as well as applying appropriate prevention. IQ Biozoom technology will be designed for home self-testing. In the near future, the company intends to focus on expanding the technology usage to measure the levels of other substances important for diabetics (diabetes package) and woman (hormone package) ‒ in saliva.

SOURCE: EuropaWire

A groundbreaking paper: Climate change is a key driver of infectious disease outbreaks in Europe

Increasing threat of vector-borne infectious diseases exacerbated by climate change. (Credit: Ingenious Buddy, stock.adobe.com)

BRUSSELS, 5-Sep-2023 — /EPR HEALTHCARE NEWS/ — The Lancet Regional Health – Europe journal has published a scientific paper on 7 August 2023 authored by a distinguished team of international researchers as part of their work in the IDAlert project. Titled “Decision-Support Tools to Build Climate Resilience Against Emerging Infectious Diseases in Europe and Beyond“, this paper introduces a transformative approach to tackle the emergence and transmission of climate-sensitive infectious diseases in Europe, informing cross-sectoral policy while improving the long-term climate resilience of health systems to infectious disease risks.

Climate change is one of several drivers of recurrent outbreaks and geographical range expansion of infectious diseases in Europe. This paper proposes a collaborative approach to develop policy-relevant indicators and decision-support tools. These tools are designed to comprehensively track and anticipate climate-induced disease risks across various domains, including environmental hazard, exposure patterns, and vulnerability factors. With a keen focus on the interconnectedness of animals, humans, and the environment, the framework promises a holistic perspective to address this multifaceted challenge.

The lead author and IDAlert project coordinator Joacim Rocklöv highlighted, “Our decision-support tools offer a multi-dimensional perspective that transcends traditional silos. By examining the nexus of animals, humans, and the environment, we’re unlocking a more comprehensive understanding of disease dynamics a pre-requisite for more timely and effective outbreak preparedness.”

The heart of this novel framework lies in the co-production of early warning and response systems with stakeholders and end-users, as well as tailored tools to assess the costs and benefits associated with climate adaptation and mitigation strategies across diverse sectors. By fostering greater resilience within regional and local health systems, the framework aims to strengthen Europe’s capacity to respond to health crises, even in the face of changing environmental conditions.

As part of its approach, the IDAlert project will integrate multi-level engagement, innovative methodologies, and novel data streams, and tap into locally generated intelligence and empirical insights through case studies. This strategy empowers experts to quantify the effects of climate-induced disease threats in areas undergoing rapid urban transformation and contending with heterogeneous health risks. The ultimate aspiration is to bridge the gap between knowledge and action, delivering an unparalleled integrated One Health—Climate Risk framework that will empower policymakers, healthcare professionals, and communities to mitigate risks and bolster resilience.

About The Lancet Regional Health – Europe Journal:
The Lancet Regional Health – Europe Journal is a prestigious journal renowned for publishing groundbreaking research on health challenges worldwide. It aims to promote the advancement of the research agenda, clinical practice and health policy in Europe with the goal of improving health outcomes for all people regionally and globally.

About the IDAlert project:
IDAlert – Infectious Disease decision-support tools and Alert systems to build climate Resilience to emerging health Threats – officially started on 1 June 2022 is a € 9.18 million project and lasts for five years. The project is funded by the European Commission under the Horizon Europe programme with Grant Agreement number 101057554. More information: www.idalertproject.eu

Note to Editors:
For more information about the paper or to request an interview with the researchers, please contact the IDAlert project: contact@idalertproject.eu.

The full paper, “Decision-Support Tools to Build Climate Resilience Against Emerging Infectious Diseases in Europe and Beyond,” is available on the Lancet Regional Health Journal website:
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(23)00120-5/fulltext

SOURCE: EuropaWire

AMBROSIA, a new HORIZON-RIA project, aims to develop a portable diagnostic unit for intelligent sepsis diagnosis

ATHENS, 9-May-2023 — /EuropaWire/ — AMBROSIA (http://ambrosia-h2022.eu/) is a new ambitious HORIZON Research and Innovation Action project that was granted under the call of “Digital and emerging technologies for competitiveness and fit for the green deal” and the topic “HORIZON-CL4-2022-DIGITAL-EMER-GING-01-03: Advanced multi-sensing systems”. AMBROSIA envisions to develop a portable diagnostic unit for intelligent sepsis diagnosis at the point-of-care (PoC).

Sepsis is a life-threatening whole-body inflammatory reaction caused by a severe infection. With mortality rates around 35%, sepsis is responsible for 11 million deaths worldwide every year. In economic terms, sepsis represents a primary cost of hospitalization in developed regions, expending up to €9 billion/year only in Germany. The window of opportunity for sepsis management is in hours: the chance of survival drops by 7.6% each hour of disease progression until an appropriate treatment is started. However, early and accurate sepsis detection is hampered due to: i) complex diagnostic criteria requiring screening of multiple targets, (ii) time-consuming methods for identifying the bacterial causes of sepsis, (iii) specimen transfers in centralized laboratories. Meeting this challenging framework can only be accomplished through the adoption of real-time and label-free sensor technologies incorporated in PoC platforms.

This is exactly where AMBROSIA steps in to transform integrated plasmo-photonic RI sensors into a disruptive solution for sepsis diagnosis at the point of care that will offer multiplexed (within a single test) quantification of multiple protein biomarkers and bacteria within a few minutes, providing also real-time disease stage classification and enabling a rapid and precise decision making for medical actuation. Specifically, AMBROSIA objectives include:

1. Development of multi-channel label-free CMOS plasmo-photonic sensors with high-sensitivity and resilience to noise.
2. Hetero-integration of InP-on-SiN through micro-transfer printing (μTP).
3. Development of an AI-based electro-optical read-out exploiting ultra-low power photonic Deep Neural Networks for disease classification.
4. Development of a PoC sepsis diagnostic unit.
5. Experimental validation of AMBROSIA sepsis diagnostic system with real samples.

The project is coordinated by the Aristotle University of Thessaloniki, Greece, and is scheduled to run for 4 years bringing together 12 partners strategically compiled from strong industrial and academic organizations including: (a) 4 universities, Aristotle University of Thessaloniki (GR), University of Bourgogne (FR), University of Southampton (UK), and University of Ioannina (GR), (b) 2 research institutes, the Catalan Institute of Nanoscience and Nanotechnology (ES), and the Vall d’Hebron Research Institute (ES), and (c) 6 companies, Ligentec (CH), SMART PHOTONICS BV (NL), X-Celeprint (IE), Argotech (CZ), microLIQUID (ES), and Biopix DNA Technology P.C. (GR).

About AMBROSIA

A MULTIPLEXED PLASMO-PHOTONIC BIOSENSING PLATFORM FOR RAPID AND INTELLIGENT SEPSIS DIAGNOSIS AT THE POINT-OF-CARE

Project ID:101093166
Call: HORIZON-CL4-2022-DIGITAL-EMERGING-01
Type of Action: HORIZON-RIA
Start Date: 01 Jan 2023
Duration: 48 months
Estimated Project Cost: €4,999,612.17
Requested EU Contribution: €3,689,509.66

Website: http://ambrosia-h2022.eu/

About BIOPIX-T

BIOPIX DNA TECHNOLOGY P.C. (https://biopix-t.com)  was founded in December 2019 in order to commercialize a novel molecular diagnostic method, developed by the founding team, for the detection of nucleic acids at the point-of-care. The company targets multiple healthcare-diagnostics related markets through the production of standardized assays for detection and monitoring of Infectious Diseases and Companion Diagnostics. Our mission is to offer portable diagnostic devices to every potential end-user, regardless of financial status, geographical location and training.

SOURCE: EuropaWire

Novartis, Lundbeck, and GSK Among Pharmaceutical Companies to Present at Patients as Partners Europe 2023

NEW YORK, NY, United States, 13-Apr-2023 — /EPR HEALTHCARE NEWS/ — The Conference Forum announced that the 7th annual European Patients as Partners® in Clinical Research conference will return to London at the Thistle Hotel Marble Arch on June 12-13, 2023. The event will showcase the progress made by pharma R&D executives with input from patients on achieving greater representation in clinical research, building trust and engagement in communities, and building truly patient-centric R&D organizations.

“We are delighted to be back in person to offer an unparalleled opportunity to hear from pharma R&D and patient advocacy together on how patient involvement gets done to drive greater efficiencies in clinical research with better outcomes,” said Valerie Bowling, Executive Director, Patients as Partners in Clinical Research Europe.

A variety of pharmaceutical companies will report on the progress they’ve made engaging communities and partnering with patients. Sanofi will open with the evolution of patient-informed research and its impact on medicine development. Novartis will be speaking on the organization’s global approach to implementing systematic and consistent patient engagement across the medicine lifecycle with a focus on measurement.

Lundbeck will share how they are generating insights through engagement with patient communities and making patient input actionable for medicines development. CSL Behring will discuss how they are evaluating clinical research sites based on patient-focused principles.

Several companies, including Regeneron, the Center for BME Health and Sanofi, will discuss their progress in increasing diversity amongst underrepresented communities in clinical research. GSK will lead a session on understanding barriers to community engagement in clinical research.

Boehringer Ingelheim will discuss the company’s approach to engaging patients throughout the clinical trial and how to leverage those patient insights to improve the process. Alnylam Pharmaceuticals will share how the organization has developed a top-down approach to integrating the patient perspective.

The conference features incredible patient advocate representation, addressing the realities of underrepresented communities to better serve them. For the first time, Patients as Partners Europe will have a patient-led session on supporting mental health for patients in clinical research.

“I look forward to hearing from patients and industry colleagues about what matters most and what has the greatest impact when partnering with patients and their communities on our efforts to new therapeutic options available,” said Deirdre BeVard, SVP, R&D Strategic Operations, CSL Behring and Patients as Partners Europe co-chair.

Key topics for 2023 include:

  • The evolution of patient informed research
  • Increasing diversity in clinical research
  • Patient access to research through digital innovation
  • Understanding barriers to community engagement in clinical research
  • Turning patient insights into action
  • Navigating patient engagement and compliance
  • Mapping and how to measure patient engagement
  • Regulatory requirements and patient engagement in drug development

To learn more about the event, and a full overview of speakers, please click here (https://theconferenceforum.org/conferences/patients-as-partners-europe/overview/)

About Patients as Partners EU
Patients as Partners is co-produced with patients, industry, academia, government and nonprofit organizations to establish a well-rounded program that addresses the needs of all stakeholders seeking to implement and advance patient involvement across the entire clinical development continuum.

About the Conference Forum
The Conference Forum is a life science industry research firm that develops conferences primarily around how to get therapeutics to patients faster. They examine and challenge the complex ecosystem of drug development and delivery, bringing ideas together from a variety of sources to help advance clinical research with common goals that are patient-focused.

They currently offer conferences for pharma/biotech professionals including R&D leaders, CEOs, business development/licensing, medical affairs/safety, chief patient officers/advocates, clinical innovation champions, investors and drug delivery specialists. The company also publishes six newsletters and produces PharmaTalkRadio and virtual events.

SOURCE: EuropaWire

MIGUN LIFE, the original brand of K healthcare, to participate at CES 2023

SEOUL, Korea, 20-Dec-2022 — /EPR HEALTHCARE NEWS/ — MIGUN LIFE (CEO Jacob Hun Cheol Chang), the originator of home medical appliance, will participate in CES 2023 world’s largest exhibition of home appliances which will be held on January at Las Vegas Convention Center in USA, and will unveil year 2023 new products.

MIGUN LIFE set up exhibition booth in Convention Center at Venetian Expo Hall and will introduce MIGUN LIFE’s products and brand to global buyers. The year 2023 new products to be unveiled this time are Re:ach RH01 and Re:ach RH02.

Product Information

Re:ach RH01 is product in a form of mat that allows us to enjoy relaxation and spine treatment. Re:ach RH02 is product in a form of mattress that allows us to enjoy both sleeping and spinal treatment which looks like a regular bed. The main feature of these products is that hidden jade massager comes out and starts spinal massage from one’s neck to hip. More than 10 acupressure rods stimulate blood spots exactly next to spine line. Once the operation is stopped, jade and acupressure rods return to inside of the mat or mattress, then you can have comfortable relaxation and sleep. Each product has leg cuffs exclusively for lower body which has functions for massaging legs and acupressure for soles of the foot. Also, they are evenly equipped with all convenient functions necessary for massage and relaxation such as thermal function, body scanning function, massage function tailored to individual’s body shape, intensity modulation massage function, relaxing music.

Personal thermal therapy appliance which was upgraded through MIGUN LIFE’s unrivaled technology Re:borne, personal ultrasound stimulating appliance Re:vive, high-frequency foot stimulator DAY:RE, these 3 products will be also exhibited.

Exhibition Booth

In the booth, products are placed in relaxed space so that visitors can experience the products comfortably and reception space for business talk are prepared separately. Furthermore, key component which shows MIGUN’s advanced technology, 2 sets of 5 thermo jades (10 thermo jades) will be exhibited with an emphasis on visitors to experience and understand MIGUN LIFE. 2 sets of 5 thermo jades (10 thermo jades) are made of 10 processed natural jades which have thermal function and it moves along the spine line and provides compression and heat.

Purpose of Participation

MIGUN LIFE has purpose to achieve from participating CES 2023. First of all, it is to promote brand and products worldwide to expand our global business in earnest from 2023 which we established 50 countries and for about 30 years. Also, it is to increase sales across the US since the establishment of US corporation in 2000. MIGUN LIFE has export record more than 5 million US dollars in the US, proceeded FDA (Food AND Drug Administration) for approval but also clinical trial at UC Irvine in the US. It explains that if MIGUN LIFE meets demand from American customers, the products will be recognized as differentiated product by going beyond global standards.

An official from MIGUN LIFE said “MIGUN LIFE, the original brand of K-healthcare, will participate CES 2023 to introduce 2023 new products and is asking for interest of MIGUN LIFE’s active role in Korea market but also in global market as well”

Homepage : http://www.migunlife.co.kr
Inquiry : +82-2-6951-2886 / Sales Rep: Andrew Yoon (migunlife_gsales@migunlife.co.kr)
Sales Rep: Andrew Yoon (migunlife_gsales@migunlife.co.kr)

SOURCE: EuropaWire

A British Girl Creates a Special Sign for Women’s Periods to Say “No” to Period Shaming

NEW YORK, 2022-Nov-21 — /EPR HEALTHCARE NEWS/ — In recent years, “menstrual shame” has become one of the most searched topics on the Internet, which caused heated discussion among netizens. Some women said they had never felt ashamed of menstruation and they even could talk about it openly. Some others said they felt period-shame when they were young; however, this feeling gradually disappeared as they grew older…

It is believed that most girls feel embarrassed or even ashamed to talk about periods when they are young. They hesitate to tell others when they feel sick during the periods; they even feel uncomfortable buying sanitary essentials from shops and try to “cover up” the embarrassment with black plastic bags.

Periods shouldn’t be taboo!

Sophia McKinstry, a girl from a university in UK, has exquisitely made a “Special Sign for Women’s Periods” to call on people to break the taboo around menstruation, remove the shame and stigma, and urge the society to face women’s physiological periods squarely. The overall outline of the Special Sign for Women’s Periods is like a drop of blood. The upper part is mainly composed of rosebuds, which shows a curling-up female who is lying on her side. The hollow part showing a few bat totem elements combines with the red shadow below to express that the woman is on her period.

When talking about the chance for the creation of the Special Sign, Sophia McKinstry said that she initially just wanted to help girls with period discomfort by designing a special sign, for example, when others see a girl wearing this sign, they will know that she is on her period and may feel tired and uncomfortable. In some cases, she probably needs a little care and understanding like a hot drink for her when eating meals together or avoiding persuading her to drink wine. She saw a piece of news that Melinda Gates liked the Chinese swimmer Fu Yuanhui for her bravely smashing period taboo during the Rio Olympics and noticed various hot discussions triggered by the Indian film Padman. After that, she gradually realized that period shame is a common phenomenon in many countries. Menstruation is perceived as unclean or shameful by girls and other people, which can be seen in all aspects of our lives. Therefore, she began to pay more attention to the topic of menstrual shame.

Sophia McKinstry stated that she wanted to make people understand through her own way that menstruation is a normal and healthy part of life for women and the traditional idea that periods are dirty should be bravely broken. Female periods should be treated equally as other physical phenomena in the society and they should not be taboo. For this purpose, she “encourages people to abandon the traditional secular ideas such as ‘menstrual taboo’ and ‘ menstrual shame’”, and integrate “may every girl does not feel embarrassed or ashamed any more when talking about menstruation” as well as other concepts and appeals into the design concept of the Special Sign.

The Special Sign for Women’s Periods has become globally accepted to mark women’s menstruation and periods. It encourages women to break the taboo of “menstrual shame”, calls on the society to stop hating “menstruation”, and represents care and understanding for women on periods.

The small sign contains infinite power. We believe that it will promote a great spirit, end the long-standing discrimination, and arouse people’s courage to challenge the secular ideas and break taboos, just like the Olympic Rings and Red Ribbons.

Via EPR Network
More Healthcare press releases

Diabeloop presents the results of the use of its Automated Insulin Delivery (AID) over the past 12 months by 4,162 patients

PARIS, 21-Sep-2022 — /EPR HEALTHCARE NEWS/ — Diabeloop, a leader in therapeutic AI applied to insulin delivery, reports today on 12 months of use of its hybrid closed-loop DBLG1 System on a large, multi-country patient cohort. While Time in Range (70-180 mg/dL) still shows constant improvement, time spent in hypoglycemia stays significantly low. Users share how these clinical results, combined with a growing trust in the algorithm has led to fewer interactions with the device and improved quality of life.

New data2: one year living with DBLG1 System
Cohort of over 4,000 patients in 5 European countries

The innovative company Diabeloop, which will be present this week at the EASD Annual Meeting 2022, shares new real-world data on its first Automated Insulin Delivery system use.

DBLG1 System reached the European market a little over a year ago with consistent utilization throughout this period, with merely 1% of users discontinuing use of the product3.

In line with previously presented data4, significant improvement in Time in Range is observed here on a much larger population. The cohort gathers 4,162 patients in five countries: Germany, Italy, Spain, The Netherlands and Switzerland. TIR gain is 17.6 percentage points over a year of real life use.

Pr. Pierre-Yves Benhamou, CMO and President of Diabeloop’s scientific committee and US advisory board, commented:

“When initiating a treatment with DBLG1, it can be expected that the recommended outcomes (i.e., a TIR>70%, a TBR<4% and a GMI< 7%) will be achieved in about half of patients. Currently in Europe, the rate of achievement with standard treatment is only 27%.”

Another significant result is that this improvement in time spent in the target range is combined with a still extremely low occurrence of hypoglycemia: 0.2% < 54 mg/dL, 1.1% < 70 mg/dL. For the patients’ clinical picture and for their overall quality of life, this means less than 20 minutes per day spent in hypoglycemia, whereas the maximum accepted in the international recommendations is 60 mins.

Andrea and Martin, users of DBLG1 System share the benefit they derived from DBLG1 System on their hypoglycemia:

“Before I started using the system, I always had restless nights, because I often got hypoglycemia at night. Now the nights are great, I have to say.”

“I feel safer knowing that I’m not going to start sweating at some point, somewhere, because I have a low. That always made me feel kind of weak. I used to work as a nurse in three shifts, so I wish DBLG1 had been available, because I didn’t really have a daily routine then, where DBLG1 would have supported me.”

Algorithm performance leads patients to entrust it with fuller meal management

In the current commercial version of DBLG1, thanks to the initial parameter (meal ratio) and intuitive food logging functionality, patients:

– have access to meal size pre-configurations (small – medium – large)
– can quickly declare their meal
– personalize the carb intake declaration.

Based on the declaration, the glucose trend at time of meal and incremental patient data, the algorithm will recommend the insulin dose to deliver and manage post-prandial time period.

Diabeloop has already announced it was working on new versions to allow optimal management without declaration. Testimonials and data5 of DBLG1 real-life use however tend to show that patients trust the currently available device’s performance enough to skip some meal declarations and/or to declare approximative carbs quantities, and still get satisfying results.

For example, for the three main daily meals (breakfast, lunch and dinner), the patients used the shortcut (small-medium-large) for half of the 45 million meals declared on DBLG1.

It has also been observed that the longer the patients use DBLG1, the less likely they tend to declare meals altogether and the system will regulate itself. On average, one less meal is declared per day after 6 months of use.

Throughout the first 12 months of commercialization, feedback from users has been tremendous, highlighting time-saving, mental load alleviation and overall quality of life improvement.

Eva shares:

“I would definitely say that the mental burden has become less, or that I have to put in less effort to get good values (…) My sleep in general has gotten much better. The blood sugar levels are much more stable. I remember when I would wake up at night or set my own alarm. That has become much better since I have the Diabeloop system. The nights are fantastic.”

Erik Huneker, co-founder and CEO of Diabeloop reacts to these new real-world data and users comments:

“There is nothing more fueling for us than seeing DBLG1 perform over many months while it contributes to people with diabetes various lifestyles and needs. We have now equipped 10,000 patients and look forward to providing more personalization, ever more simplicity of use and more choices…to more and more people with diabetes.”

DIABELOOP AT EASD, September 20-23:
Booth M06
Meet the Expert session, September 21, 10:00 – 10:30 am
Supporting patient empowerment and improving glycemic outcomes with connected pens and artificial intelligence – From DBLG1 to DBL-4pen.
Networking Hub – with Erik Huneker, Pr. Lutz Heinemann & Pr. Pierre-Yves Benhamou
Platinum sponsor of #dedoc voices program

SOURCE: EuropaWire

Diabeloop, a high-growth health tech firm that automates the treatment and the management of diabetes, announces EUR 70 million funding

PARIS, 2-Jun-2022 — /EPR HEALTHCARE NEWS/ — Diabeloop secures 70 million euros to pursue its solid and sustained growth strategy.

The company, an Automated Insulin Delivery pioneer, develops machine-learning software for diabetes treatment. Its highly sophisticated algorithms are integrated into easy-to-use products helping facilitate chronic disease management impacting patients’ clinical outcomes and their quality of life.

Diabeloop has seen impressive growth in the last few years with two products on the European market, rapidly approaching 10,000 equipped patients one year after commercial launch and major developments with various device partners.

The first closed-loop solutions commercialized by Diabeloop offer personalized management for Type 1 (DBLG1) and highly unstable Type 1 diabetes (DBL-hu). By connecting a Continuous Glucose Monitoring device (CGM) and an insulin pump, Diabeloop’s world-leading algorithms analyze data in real time and automate insulin delivery. It transforms the lives of people with diabetes by taking over many of the therapeutic decisions that used to fall to patients.

Erik Huneker, founder & CEO of Diabeloop, declares: “Being able in 2021 to bring the benefits of our products to thousands of patients and hearing their enthusiasm, is why all of us at Diabeloop work so hard. The financing round announced today recognizes the team’s successes, and more importantly, the great opportunities ahead.”

The financing round is led by prominent private equity player LBO France. The Venture division of the sustainability-conscious private equity fund is a European leader in digital health, supporting young companies with ambitious projects showing international footprints.

“Diabeloop’s team has developed a unique data driven product that has the potential to revolutionize the daily life of millions of diabetic patients by taking away most of their daily mental burden and significantly improving the control of their disease. We are eager to join the investor base and help the company become a global leader in diabetes closed-loop software solutions,” says Valery Huot, Partner, Head of Venture at LBO France.

International healthcare leader Terumo Corporation also participates in Diabeloop’s Series C round. After entering into development agreements with one another in 2020, Terumo extended this to a comprehensive strategic partnership agreement with Diabeloop in 2021.

“We are excited that Diabeloop successfully completed this important milestone and the great opportunities will continue to expand for all corners of the world. Together with Diabeloop, we are committed that we will be able to contribute to all stakeholders by providing patient-centric and personalized solutions,” comments Hikaru Samejima, President of Terumo’s Medical Care Solutions Company.

Innovacom, a key player in the French and European startup community specialized in deep-tech and industrial projects, joins LBO France and Terumo Corporation as new investors.

Comforted by the commercial launch of Diabeloop first devices and the break-through potential of its projects to address a 10-million patients market in the mid-term, previous investors CERITD, CEMAG invest, Kreaxi, Supernova Invest, AGIR A DOM., Crédit Agricole, Odyssée Venture, UI Investissement (Sofimac) and Promontoires all have decided to reinvest.

Additionally, Bpifrance and the historical bank pool are supporting Diabeloop via debt financing.

“We are grateful for the confidence of our existing investors and proud of our distinguished new financial and industrial shareholders. I have full trust in the talent and commitment of the Diabeloop teams to pursue their groundbreaking value creation path for patients and become a trusted leader and partner in the highly reactive diabetes market,” concludes Catherine Dunand, Diabeloop’s Chairman of the Board.

In 2019, Diabeloop secured the highest recorded European financing round in Therapeutic Artificial Intelligence and went on to commercially launch two products, with several thousand patients equipped in less than a year. Their CE-marked data visualization platform accompanies healthcare professionals and patients as a telemedicine and remote patient monitoring solution. High-impact projects such as the adaptation of the core-algorithm to the multi-million users Connected Pen market and development of smart-watch devices also have contributed to Diabeloop’s tremendous momentum.

About Diabeloop
Diabeloop’s mission: Making innovation accessible to people living with diabetes, improving clinical results while relieving them of their constant mental burden.

Created in 2015, Diabeloop is a high-growth company that offers AI-based, personalized solutions to automate the treatment and the management of diabetes. DBLG1 System, Diabeloop’s first medical device for automated insulin delivery (AID) and DBL-hu, its solution for highly unstable Type 1 diabetes management, are both CE-marked and being deployed in Europe. Diabeloop just completed its Series C financing round, securing 70 million euros, to accelerate its commercial roll-out, support its sustained growth strategy and its high-impact projects.

Today, Diabeloop gathers the personality, passion, and skills of over 160 talented individuals who work hard to improve the quality of life for every person living with diabetes.

About LBO France
With €6.6 billion of capital raised since its inception, as a key player in private equity, LBO France is supporting growing French and Italian companies for more than 30 years.

Its investment strategy is based on five distinct segments managed by dedicated teams:

(i) Mid Cap Buyout through the White Knight funds, and Small Cap Buyout through the Small Caps Opportunities funds,
(ii) Venture capital through the Digital Health funds,
(iii) Real estate through the French White Stone funds, OPCI Lapillus, impact fund Newstone and the Italian management company Polis Fondi SGR
(iv) Debt, notably in Italy through the Vita Superbonus program to finance energy efficiency in real estate assets
(v) Public Equity through the France Développement fund

LBO France is 100 % owned by its management and employs nearly 70 professionals.

SOURCE: EuropaWire

Diabeloop to integrate insulin pens into its hybrid closed-loop system using a unique app

PARIS, 12-Apr-2022 — /EPR HEALTHCARE NEWS/ — Diabeloop, a pioneer in the field of therapeutic artificial intelligence, leverages the potential of its diabetes technology to enable the integration of insulin pens into its hybrid closed-loop system using a unique app. With DBL-4pen, Diabeloop offers new opportunities for personalized diabetes management for people with Type 1 and Type 2 diabetes, further advancing the quality of patient care.

Diabeloop opens a new segment in the insulin therapy market

Several tens of millions of people worldwide require insulin everyday. However, only 2 million of them1 are equipped with insulin pumps, because of their relative complexity and significant cost. Most diabetes patients in Europe and the U.S. on intensive insulin therapy are multiple daily insulin injections (MDI) pen users.

Diabeloop is developing a product for people living with diabetes who do not have access or want to wear an insulin pump. Using self-learning algorithms, DBL-4pen will bring most of the clinical improvement from DBLG1’s closed-loop to insulin pen users, while the overall cost will be significantly lower for the payer.

DBL-4pen: real-time mobile insulin dosing and telemedicine solution

People on multiple daily insulin injections using pens face the challenge of determining the correct amount and timing of insulin depending on individual blood glucose levels, physiology and lifestyle. To reduce hypoglycemia, risks of associated complications while lowering the mental burden of managing diabetes for patients using insulin pens, Diabeloop is developing a unique smartphone app that embeds its self-learning algorithm. The app is connected via Bluetooth® to a connected insulin pen and a CGM that measures blood glucose levels every 5 minutes.

On the way to more automation, DBL-4pen requires a minimal input from users. They only need to enter meals and physical activities into the app. DBL-4pen then automatically recommends the ideal insulin dose in real time, which can be delivered via the pen with no more calculation to do.

In addition, the measured data can be transmitted to the physician, healthcare providers or family members via YourLoops, the cloud based data visualization platform, if the patient so desires.

Strong partnerships to foster interoperability

DBL-4pen complements Diabeloop’s existing product line with another user-friendly and personalized solution that offers more control and customization possibilities regarding diabetes management.

“The integration of insulin pens into hybrid closed-loop systems is a substantial progress. Especially diabetes patients for whom pump therapy is a hurdle can benefit from this new solution. Moreover, diabetes therapy with insulin pens can be a viable solution for different healthcare systems,” said Prof. Hélène Hanaire of the University Hospital of Toulouse.

Diabeloop announces the extension of its partnership with BIOCORP, a French company specialized in the development and manufacturing of medical devices and connected healthcare solutions, to integrate Mallya®, their smart cap for insulin injection pens into Diabeloop’s technological environment.

This and other planned partnerships are expected to create new opportunities to bring Diabeloop’s interoperable technologies to people with diabetes who use insulin pens for their daily multiple injections.

“With DBL-4pen, we are able to bring the power of self-learning algorithms and connectivity to the majority of people who can not or do not want to wear an insulin pump. The combination of smart sensors for insulin pens with our self-learning algorithm gives us the opportunity to integrate a wide range of insulin pens into our hybrid closed-loop system in the future. Our goal is for this innovative solution to be compatible with almost all pens on the market,” said Erik Huneker, CEO and co-founder of Diabeloop.

Dynamic bolus insulin titration doses

DBL-4pen is currently a unique solution for MDI patients to dynamically titrate bolus insulin doses. Personalization is at the core of this solution because the app takes into account both entered meals and physical activities, as well as glucose trend, and uses the entire patient history to fine-tune bolus amounts based on the patient’s response to previous boluses.

“DBL-4pen offers a customized solution for MDI patients that can be integrated into hybrid closed-loop systems. Currently, we are in the process of launching a clinical trial in France to strengthen Diabeloop’s positioning in the insulin pen therapy market,” said Marc Julien, Chief Operating Officer of Diabeloop.

About Diabeloop
Created in 2015, Diabeloop is a high-growth company that offers AI-based, personalized solutions to improve clinical outcomes for people with diabetes while relieving them of their constant mental burden. DBLG1 System, Diabeloop’s first medical device for automated insulin delivery (AID) and DBL-hu, its solution for highly unstable Type 1 diabetes management, are both CE-marked and being deployed in Europe.

A second round of financing of 31 million euros, concluded at the end of 2019, supported the international commercial rollout of DBLG1 iController and Diabeloop’s ambitious R&D program. Today, Diabeloop gathers the personality, passion, and skills of over 160 talented individuals who work hard to improve the quality of life for every person living with diabetes.
——————
Reference:
1 2021 internal extrapolation based on Seagrove Partners and Simon-Kucher reports data

——————–
Meet Diabeloop at ATTD 2022 (27-30 April 2022, Barcelona, Spain) or contact us for further information at: partnership@diabeloop.fr

SOURCE: EuropaWire

Silencil Reviews: A Scam Supplement Or Does It Really Treat Tinnitus – Critical Silencil Review

NEW YORK, 2022-Mar-24 — /EPR HEALTHCARE NEWS/ — It is no news that tinnitus has been considered an incurable health condition ever since it was discovered. Hence, whereas doctors and clinicians usually prescribe antidepressants or anxiety-relieving medications to assist reduce the internal noise, there are no medications specifically designed to help put an end to it. But can Silencil really cure tinnitus? A YES OR A NO!

The fact that no one believes tinnitus has a cure stems from the story that some people have attempted numerous approaches in an attempt to get rid of their ringing in the ears without success. Nonetheless, recent advancements in medical science are taking us one step closer to finding a cure – brain inflammation as the cause of tinnitus. Fortunately, the Silencil team has rallied around this cause (brain inflammation), and they are determined to see it through.

MUST SEE: VISIT THE OFFICIAL WEBSITE TODAY FOR YOUR OWN SUPPLEMENT
According to the manufacturer, Silencil was designed to be almost your one and only true protection against tinnitus of all forms. It is a new nutritional supplement that is intended to reduce ringing in the ears as well as any associated symptoms that may occur as a result of the condition by reducing brain inflammation. Silencil is believed to really solve tinnitus by targeting the underlying problem. This Silencil Review is meant to explain everything about this supplement. Real-world customers and doctors have endorsed it as being tested, dependable, approved, effective, potent, legitimate and reliable.

What Is Silencil?
Silencil is a natural tinnitus supplement made up of 28 clinically approved plant extracts and vitamins that have been shown to be effective in treating tinnitus by reducing brain inflammation. It improves overall brain function, as well as strengthening the immune system and repairing any damage that has occurred, thereby curing tinnitus.

CLICK HERE TO BUY THIS NUTRITIONAL SUPPLEMENT FOR YOUR TINNITUS ON THE OFFICIAL WEBSITE
Silencil is a brain-health supplement / vitamin for tinnitus which works to restore your brain and body’s normal function, ultimately treating you of the condition. Simultaneously providing users with a natural blend of plant and vitamin extracts that work on nerve cells and brain tissue, Silencil’s primary purpose is to improve the user’s ability to hear in all ramifications. While Silencil does assist to decrease the ringing in the ears, it does so primarily through the reduction of inflammation and the re-establishment of neural connections inside the brain.

Truly, Silencil should not be seen as a miracle solution for curing tinnitus, and thus, it should not be expected to produce results overnight. It is rather a dietary supplement which is vested with totally lowering the symptoms of tinnitus as a whole. It accomplishes relief to tinnitus sufferers by identifying and resolving the fundamental root of the problem known as brain inflammation. This is only possible if you have adhered to the manufacturer’s prescription and procedure.

According to general consensus, tinnitus is caused by an issue with one’s hearing. However, the inventor of Silencil believes that electrical misfires (inflammation) in the brain are responsible for a considerable percentage of the ringing in one’s ears and the Silencil pills are designed to address it as effectively as possible.

Is Silencil a legitimate treatment for tinnitus, or does it come with potentially serious side effects and allergies? Of course, this Silencil pill addresses and heals brain inflammation, which is the underlying cause of tinnitus in most cases. It is 100 percent legitimate, and the success stories that have been shared are genuine. Because the components in Silencil have all been approved by the FDA and professionally evaluated, there are no known negative side effects from using it. When the supplement is taken as directed, the pills are delivered directly to the brain, where they work to repair the damaged chain, alleviating the continual ringing sound in the ear.

This natural supplement is now widely acknowledged as one of the most effective natural remedies available for the treatment of tinnitus on a global scale. Millions of real clients all over the world have benefited from this superior supplement and have stated that the ringing or buzzing in their ears has been eliminated completely.

Via EPR Network
More Healthcare press releases

EU Patients as Partners in Medicines Development conference to be held virtually on Jan 24-25, 2022

(PRESS RELEASE) New York, NY, United States, 5-Jan-2021 — /EPR HEALTHCARE NEWS/ — The Conference Forum announced the launch of the 6th annual EU Patients as Partners in Medicines Development conference to take place virtually on January 24-25th, 2022 GMT time.

​​This annual event, the first of its kind in Europe, will feature successful collaborations between patients and pharma where patient input directly impacted aspects of how a pharmaceutical company either designed or conducted a clinical trial.

Of the 20 sessions, half include a patient or patient advocate. This two-day program will demonstrate how patient-led research can improve the way pharma conducts clinical trials.

Examples include UCB developing new assessment tools to measure the effectiveness of novel treatments for Parkinson’s disease, changes in the design and implementation of an MS trial for greater patient engagement, and the development of a new toolkit to change the way patients are compensated for their contributions in clinical research.

“Patients have become more empowered,” says co-chair Michaela Dinboeck, Head, Center of Excellence for Patient Engagement at Novartis. “So patient engagement must be integrated into the DNA of how medicines are developed, approved, and used. Patients as Partners Europe will provide Pharma with valuable insights on how to achieve this.”

Participating pharma companies include Novartis, Pfizer, Merck KGaA, EMD Serono, Janssen, Johnson & Johnson, GSK, Ipsen, UCB, Takeda, AbbVie, Noema Pharma, Gilead Sciences, Regeneron, and Pierre Fabre.

Other topics to be addressed include: Scaling patient engagement activities company-wide, engaging patients in early clinical development, leveraging social media to gain patient insights, diversity and inclusion in research and updates on patient engagement activities in Eastern Europe.

To learn more, please visit Patients as Partners Europe.

SOURCE: EuropaWire

Origami and citoQualis will work together to help Medical Device startups get products to global markets faster

KFAR SABA, Israel, 9-Nov-2021 — /EPR HEALTHCARE NEWS/ — Origami, a leading provider of no-code business process automation software for Medical Device and other industries, and citoQualis, a regulatory and business advisory leader for EU Medical Device companies, are announcing a partnership to help Medical Device startups get products to global markets faster.

Medical Device startups face unique pressures due to numerous country-specific regulations. This new partnership will help companies efficiently manage their regulatory approval processes, and enable rapid business growth.

Origami’s medical device customers operate around the world. With recent EU regulatory updates, companies are seeking strategic regulatory and business guidance to help them get and maintain product approval in that geography. The new partnership will provide Origami customers with access to citoQualis expertise in business and complex regulatory landscapes.

The citoQualis team points out that Medical Device startups have global workforces that “expect to access their systems from wherever they’re located, and to use those systems to collaborate internally and with citoQualis” says Mr. Wolfgang Werner, CEO of citoQualis.

According to Mr. Werner, “As advisors, it’s our job to identify opportunities and share our insights. For startups, the faster a product moves from idea to production, the better. With Origami’s flexibility, we are able to give our clients a software option that works for them now and as they scale.”

Germany and other EU countries have strong medical device startup ecosystems, which citoQualis is well connected to. Origami is excited to work with citoQualis and the startups they advise, noting how both companies focus their solutions and teams on helping customers succeed in complex environments.

Yaniv Shimony, CEO of Origami says “startup CEOs recognize Origami’s business value, in that they always have the solution their company needs. When you create a new and innovative medical device, using inflexible software point solutions slows your business down. With Origami, information is instantly available about any part of your business such as sales, quality, design, product approvals, manufacturing, equipment maintenance, purchasing, supplier compliance, invoicing, complaints and more.”

Existing customers will be able to maintain and expand EU market access by working with local regulatory experts, facilitating hundreds of millions of Euros of revenue.

SOURCE: EuropaWire

Pr. Pierre-Yves Benhamou: The outcomes observed in 1,000 patients using Diabeloop DBLG1 are, indeed, very good and encouraging

PARIS, 28-Sep-2021 — /EPR HEALTHCARE NEWS/ —

Real-life data confirm clinical and pre-launch data: TIR significantly improved

Today, Diabeloop presents data¹ from a 1,000 patients equipped with DBLG1 System with Accu-Chek Insight insulin pump in Germany. One of the main insights unveiled is an overall Time in optimal glucose Range (70-180 mg/dL) of 73.4% for the whole cohort of patients.

When looking specifically at data² from patients whose HbA1c was available at initiation, it can be observed that Time In Range improved 17.1 percentage points. This result is consistent with results which have been previously published pre-launch³ showing an increase in Time In Range of 16.7 percentage points.

Hypoglycemia reduction a huge factor for an improved quality of life

Data also showed a significant reduction of time spent in hypoglycemia with Time below 70 mg/dL at 1% while time below 54 mg/dL was 0.2%. This outcome surpasses the targets of the 2019 International Consensus.

Feedback of people with diabetes and their caregivers have shown that reducing hypoglycemia is very important. In addition to the life-threatening risks associated with hypoglycemia, discomfort and a decreased quality of life weighs heavily on people experiencing it regularly.

Pre-launch patients
“It (diabetes) had a big impact on my professional life (…) because of my hypoglycemia.”
“I have almost eliminated lows (…), especially at night, which is important!”

Pr. Pierre-Yves Benhamou commented: “The 2019 International Consensus on Time in Range aimed at achieving >70% in range 70-180 mg/dL, <4% below 70 mg/dL and <1% below 54 mg/dL in the majority of people with type 1 diabetes. This means over 16 hours in target range and less than 1 hour below range. The outcomes observed in 1,000 patients using DBLG1 are, indeed, very good and encouraging.”

Patient satisfaction is high

In the 5 countries where DBLG1 System is currently available, feedback from equipped patients has been very positive about its impact on TIR and hypoglycemia, in addition to the system’s ease of use and enhancement of quality of life.

Public social media posts:
“87% TIR, no hypos”
“The result (related to sport): quite conservative but great. No hypo.”
“Very intuitive, little information needed to provide at initiation.”
“I am absolutely delighted. Sometimes I even forget that I have diabetes.
I let it (DBLG1) do the math and success shows.”

Erik Huneker, founder and co-CEO of Diabeloop, who will be presenting the data at EASD4 declared: “Looking at the great results and listening to patient feedback on real-life experiences with our system has been a great reward for our work, and encourages us to make the system even better going forward. We will be able to bring DBGL1 quickly to many more patients in Europe while we keep working on bringing more choices, more interoperability, and more solutions to people with diabetes”.

About Diabeloop
Created in 2015, Diabeloop is a high-growth company that offers AI-based, personalized solutions to improve clinical outcomes for people with diabetes while relieving them of their constant mental burden. DBLG1 System, Diabeloop’s first medical device for automated insulin delivery (AID) and DBL-hu, its solution for highly unstable Type 1 diabetes management, are both CE-marked and being deployed in Europe.

A second round of financing of 31 million euros, concluded at the end of 2019, supported the international commercial rollout of the DBLG1 iController and Diabeloop’s ambitious R&D program. Today, Diabeloop gathers the personality, passion, and skills of more than 100 talented individuals who work hard to improve the quality of life for every person living with insulin-dependent diabetes.

About DBLG1
DBLG1 is a self-learning algorithm that automates and personalizes the treatment of Type 1 diabetes. The therapeutic artificial intelligence contributes to reducing the heavy mental burden associated with this chronic condition. Hosted on a dedicated handset, it is connected to a continuous glucose monitor (CGM) and an insulin pump. It analyzes the data in real time, and decides whether to maintain current settings, adjust or stop basal insulin delivery to avoid a predicted low/high or deliver a bolus to correct a high.

YourLoops, Diabeloop’s data visualization platform allows patients to access data generated by DBLG1 and share them with his/hers healthcare team.

SOURCE: EuropaWire

Het DBLG1-algoritme: eenvoudige installatie, gebruiksvriendelijk, ontworpeyyn voor elk diabetes type 1 profiel

PARIJS, 2-Jun-2021 — /EPR HEALTHCARE NEWS/ — Vanaf het begin heeft Diabeloop innovatieve systemen ontwikkeld om de behandeling van diabetes type 1 te automatiseren en te personaliseren, waarbij altijd rekening wordt gehouden met de optiek van de patiënt. Het Franse bedrijf streeft ernaar autonomie te geven aan mensen die met diabetes type 1 leven en tegelijkertijd de gebruikerservaring te optimaliseren zodat behandeling van diabetes eenvoudiger en minder ingrijpend is. Het DBLG1-algoritme biedt een bevredigende, geautomatiseerde en gepersonaliseerde ervaring met minimale input van de patiënt.

DBLG1: eenvoudige installatie, gebruiksvriendelijk, ontworpen voor elk diabetes type 1 profiel

De zware mentale last op de schouders van mensen met diabetes type 1 verlichten, begint in de eerste fasen van de ervaring met DBLG1. Gebruikers hoeven maar 4 gegevens in te voeren in het allernieuwste DBLG1-algoritme voor een veilige, geautomatiseerde en gepersonaliseerde insuline-afgifte. In de opzetfase voeren gebruikers van DBLG1 hun lichaamsgewicht in, hun totale dagelijkse insulinedosis (TDD), hun gebruikelijke maaltijden (in grammen koolhydraten) en hun basale insulinebehoefte (alleen voor open-loop). Voor het Diabeloop-algoritme zijn geen ingewikkelde berekeningen nodig. Gebruikers hoeven hun maaltijdratio niet uit te zoeken, noch hun insuline gevoeligheidsfactor noch hun insuline actiecurve.

De 4 gegevens die de patiënt in de beginfase invoert, zijn voldoende voor het DBLG1 zelflerend algoritme om te functioneren, te berekenen en de insulinedosis zo nodig elke vijf minuten aan te passen.

“We hebben het DBLG1-algoritme zo ontworpen dat het zo eenvoudig mogelijk in gebruik is voor mensen met diabetes type 1 en gebruikers tegelijkertijd de gelegenheid hebben bepaalde parameters nauwkeuriger in te stellen afhankelijk van hun specifieke behoeften en/of leefstijl. Het algoritme houdt automatisch rekening met eventuele wijzigingen die mensen invoeren. Het DBLG1-algoritme optimaliseert de werking automatisch zonder dat de patiënt hier iets voor hoeft te doen. Wijzigingen verlopen op die manier heel soepel en worden vrijwel “onzichtbaar” voor de gebruikers van het systeem“ – vertelde Yousra Tourki, Head of Algorithms Design bij Diabeloop.

Naast de eerste input biedt het DBLG1 System ook de mogelijkheid aan mensen die met diabetes type 1 leven om de behandeling en beheersing van hun diabetes nauwkeurig in te stellen met behulp van aanpasbare instellingen zoals de agressiviteit van het algoritme, de grenswaarden van hypo’s en hypers en de streefwaarde van de glucosespiegel.

Nicole Wetzels, Trainer voor Roche Diabetes Care in Nederland en gebruikster van het DBLG1 System met Accu-Check Insight, vertelt: “Ik leef al meer dan 42 jaar met diabetes type 1 en ben een paar maanden geleden begonnen met het gebruik van het DBLG1 System met een Accu-Chek insulinepomp. De opzet was heel eenvoudig: de batterij in het apparaat doen, de handset opladen en maar 4 parameters invoeren. Het invoeren van een maaltijd is een van de weinige dingen die ik zelf moet doen en ook dat is heel simpel! Maar ik heb tevens de mogelijkheid het systeem te personaliseren door bepaalde instellingen aan te passen zoals de streefwaarde van de glucosespiegel of de grenswaarden voor de hypo … Met hele kleine acties heb ik hele goede resultaten. Dankzij dit AID-systeem hoef ik niet meer de hele dag bezig te zijn met het beheersen en behandelen van mijn diabetes. Het is net of mijn diabetes type 1 op vakantie is!”

DBLG1 AID-systeem: minimale input van de patiënt nodig

Om de bruikbaarheid van het DBLG1 System te beoordelen heeft Diabeloop een wetenschappelijk onderzoek uitgevoerd op basis van reële gegevens afkomstig uit de klinisch proef (1) die vóór de lancering vanhet systeem is gerealiseerd. Het doel was het analyseren van het aantal instellingswijzingen door mensen die het systeem in het dagelijkse leven gebruiken. In de eerste week dat patiënten het DBLG1 System gebruikten, voerden ze gemiddeld slechts 1.6 instellingswijzigingen uit (± 2.3), en maar 0.2 wijziging (± 0.5) in de laatste week van de proef na 11 weken gebruik.

De belangrijkste conclusie is dat in het dagelijkse leven, wanneer de gebruikers zich niet in een beheerste omgeving bevinden zonder specifieke medische follow-up en/of aanbevelingen voor instellingswijzigingen van hun zorgteam, de mensen uitgerust met het DBGL1 System minimale aanpassingen hoeven uit te voeren om te profiteren van een bevredigende, geautomatiseerde en gepersonaliseerde diabetesbehandeling.

Verdere wetenschappelijke analyse (2) toont de gebruiksvriendelijkheid aan van het Automated Insulin Delivery-systeem van Diabeloop. Deze analyse gaf aan dat in de eerste week, 50% van de mensen die het DBLG1 System gebruikten, geen instellingswijzigingen uitvoerden. Bovendien wijzigden meer dan 85% van de mensen uitgerust met het systeem geen enkele instelling gedurende de 8ste week van gebruik.

Dit bevestigt dat het zelflerend algoritme van Diabeloop vanaf de beginfase de behandeling van diabetes type 1 optimaliseert en minimale input van de patiënt nodig heeft om de vereiste ondersteuning te bieden.

Bernhard Gehr, arts en diabetoloog, Centrum voor Diabetes en Metabole ziekten, gespecialiseerde kliniek m&i Fachklinik Bad Heilbrunn, licht toe: “Ik gebruik het DBLG1 System met de Accu-Chek Insight insulinepomp. De opzet en de eerste handelingen zijn zeer eenvoudig. De eenvoud van de gebruikersinterface maakt snelle en makkelijke invoer van de benodigde informatie mogelijk. Ik ben echt onder de indruk van de prestaties van het DBLG1 System. Vanaf de eerste dag had ik een goede controle over mijn stofwisseling. Ik heb veel meer gemoedsrust aangezien ik veel minder aan mijn diabetes hoef te denken! Dit systeem vereist minder tot vrijwel geen micromanagement van mijn behandeling. Ik was aangenaam verrast over hoe goed het algoritme tijdens de eerste nacht functioneerde, met zo weinig input in de beginfase.”

Met DBLG1 beheersen mensen hun eigen diabetesbehandeling

Het DBLG1 System is gebruiksvriendelijk en kan gepersonaliseerd worden zodat mensen die met diabetes leven verschillende instellingen kunnen beheersen.

In het dagelijkse leven biedt het DBLG1 System mensen de mogelijkheid de aan te passen zodat insuline-afgifte bijgesteld wordt om een hypo of hyper te voorkomen. Een van de onderzoeken (3) van Diabeloop, gepresenteerd op ATTD 2021, onthulde dat een daling van de glucosespiegel streefwaarde over het algemeen een vergelijkbare daling van de gemiddelde glucospiegel tot gevolg heeft. Bijvoorbeeld, -10% van de glucosespiegel streefwaarde leidt tot -10% van de gemiddelde glucosespiegel.

In overeenstemming met de missie van Diabeloop om de zware mentale last op de schouders van mensen met diabetes type 1 te verlichten en hen een ongestoord leven te bieden, bevat het systeem een Zen-modus, ontwikkeld op basis van de ervaringen van patiënten. Deze modus verhoogt tijdelijk de doelwaarde van de bloedsuikerspiegel: om rustig naar de bioscoop te gaan of een vergadering bij te wonen zonder een verstorende hypoglykemie en de bijbehorende waarschuwingssignalen, kunnen gebruikers de Zen-modus aanzetten zodat hun glucosespiegel tijdelijk en voor een door hen ingestelde tijd verhoogd wordt.

Een persoon die het DBLG1 System met Accu-Check Insight insulinepomp gebruikt, vertelde: “Zen-modus is voor al die momenten waarop je je “veiliger” wil voelen: tijdens het autorijden, op school, tijdens een examen.”

Een wetenschappelijk onderzoek (4) geleid door Diabeloop en gepresenteerd op ATTD 2021, toonde aan dat 90 minuten na de activering van de Zen-modus, de impact op de gemiddelde glucosespiegel gestabiliseerd was zonder de hyperglykemie te verlengen.

De conclusie is dat, voor een tijd die door de patiënt wordt bepaald, de Zen-modus de gebruikers uit een hypo houdt en tevens een hyper voorkomt. De Zen-modus leidt tot een lichte verhoging van de gemiddelde glykemie met een zeer beperkte impact op de time-in-range.

Het eenvoudige gebruik van het DBLG1 zelflerend algoritme draagt bij tot een ongecompliceerde diabetesbehandeling en haalt een mentale last van de schouders van mensen die leven met deze chronische ziekte zodat ze ongestoord kunnen leven!

SOURCE: EuropaWire

The biggest dedicated CBD & medical cannabis event in Europe takes place online between 28 and 30 April

LONDON, 21-Apr-2021 — /EPR HEALTHCARE NEWS/ — The CANNAVIST, the UK & Ireland’s essential guide to CBD & medical cannabis, presents CBD Live Europe, the biggest dedicated CBD & medical cannabis event to focus on the European hemp & CBD community this year. This free, virtual event takes place April 28-30.

CBD Live Europe follows the success of two similar events held by the publication in 2020. The virtual exhibition complete with an online auditorium is for consumers, patients, cannabis advocates, and business professionals across the continent.

An online exhibition hall will welcome more than 100 CBD brands, distributors and manufacturers while the auditorium will present three days of live educational material.

Day 1 will see Europe’s leading industry professionals take to the stage on pivotal issues including the post-pandemic hemp sector, regulation, FMCG and the importance of technology in unlocking the potential of cannabis.

Among the speakers to dominate on the B2B day will be Tim Phillips, founder of market intelligence firm CBD-Intel, Catherine Wilson, VP of the European Industrial Hemp Association and the co-founders of the world’s first CBD and hemp exchange, CanXchange.

Day 2 will welcome clinicians, researchers, founders and patients as Europe’s leading medical cannabis advocates share their experience and knowledge.

The line up for this medical cannabis and advocacy themed day will feature representatives from the European Cannabis Advocacy Network and high-profile campaigners, Charlotte & Billy Caldwell.

Day 3 will see a combination of CBD content aimed at health & wellbeing and personal growth goals.

From ‘How to launch your own CBD brand’ to our ‘Rewind, Reset & Reconnect’ online guided meditation, day 3 will focus the mind to end the week on a high note.

A total of 40 speakers will take over the auditorium at CBD Live Europe.

The event will take place entirely online at no cost to visitors to maximise this learning opportunity and make cannabis education more accessible. Those with an interest in CBD & medical cannabis from around the world are invited to log on for free.

CBD Live Europe will be live on virtual exhibition platform, VOXPO Events. In registering for CBD Live Europe, visitors will automatically be entered into a draw for a chance to win €500 worth of CBD goodies.

Visit voxpo-event.com to register. Visit this link to view the CBD Live Europe Auditorium Line Up.

SOURCE: EuropaWire

AirGuard™ – washable, reusable, approved 5-Layered Nano-PTFE filtering technology cloth face mask with BFE of over 95%

BOLOGNA, Italy, 31-Mar-2021 — /EPR HEALTHCARE NEWS/ — Creative Concepts Manufacturing Group announces campaign launch of their new innovative cloth mask – AirGuard™. The tested and approved 5-Layered Nano-PTFE filtering technology cloth face mask that is washable, reusable, and that has a bacterial filtration efficiency (BFE) of over 95%. Creative Concepts is ready to secure worldwide distribution and is proud to be a significant part of the solution in helping to protect against the spread of the COVID-19 virus.

Creative Concepts Manufacturing Group is a leading manufacturer of various inventions, creators of the GoTech™ Cordless Technology, and with over 4 decades of experience in the OEM/ODM and License Manufacturing, its Product Managers and owners, Vin and Joe Advani are pleased to announce the launch of their new PPE (Personal Protective Equipment) – the AIRGUARD cloth face mask with the goal of preventing individuals from spreading the COVID-19 virus, while ensuring the safety and comfort in wearing the mask.

ABOUT AIRGUARD™
According to the US CDC and European health authorities, 5 layer or equivalent face masks are mandatory and are the most protective type of a mask in preventing the spread of viruses. Most masks are either uncomfortable and do not help in filtering the size of the microns in the air. Available 3-ply masks can only be worn once before being disposed which creates a lot of pollution – not to mention waste of money. Creative Concepts took those negatives and created something positive – the AIRGUARD. It has a 5-Layer Nano-PTFE filtering technology that has a greater than 95% bacterial filtration efficiency against 0.3 micron particles in the air (like the COVID-19 virus), an equivalency of the N95 respirator. AIRGUARD™ is made from anti-bacterial breathable cotton that makes the airflow smooth and comfortable when wearing. Furthermore, the AIRGUARD™ cloth mask is hypoallergenic and has anti-microbial properties so you do not feel itchy or suffocated. The best part about the AIRGUARD™ cloth mask is that it is washable, reusable and sweat resistant. You can wash or put the AIRGUARD™ mask in the washing machine and reuse them with the same filtering properties and comfort. The AIRGUARD™ can be washed and reused up to 50 times. The outer layer is water-repellent and will not get wet from sweat during your workout or exercise.

Most cloth masks available in the market now have a maximum of 2 or 3 layers and has less or no filtering properties against harmful micron particles in the air.

As per the Director of National Institute of Health, Dr. Anthony S. Fauci – Wearing multiple layers of mask just “makes common sense” and “likely would be more effective”. AIRGUARD™ is the only 5-Layered reusable cloth mask that is more effective in preventing the spread of the virus.

AIRGUARD™ is being distributed worldwide. For more information on AIRGUARD™ cloth mask please visit

http://www.BuyAirGuardMask.com

AIRGUARD™ MASK COMPLIANCE
The AIRGUARD™ reusable cloth mask has passed several mandatory testing required by law and to provide a sense of protection for its consumers. Following are the testing approvals sought by Creative Concepts on the AIRGUARD™ by authorized testing bodies like SGS, Nelson Labs, Intertek, Bureau Veritas and UL.

  • SYNTHETIC BLOOD PENETRATION RESISTANCE (ASTM F1862 under 120 mmHg)
  • 42 CFR PART 84 – NaCI (N95 PARTICULATE FILTER EFFICIENCY)
  • EN14683:2019+AC:2019 (BACTERIAL FILTRATION EFFICIENCY-BFE)
  • FLAMMABILITY CLASS 1 (16 CFR 1610)
  • ANTI-BACTERIAL FINISHES ON TEXTILE (AATC 100-2019)
  • REACH TESTING (FOR EUROPE)
  • Face Fit Test

Via EPR Network
More Healthcare press releases

Smart Wearables in Healthcare Market – Latest Scenario On Innovation, Revolutionary Opportunities & Top Consumers 2027

Albany, New York, 2021-Mar-23 — /EPR HEALTHCARE NEWS/ — The report titled “Smart Wearables in Healthcare Market” offers a primary impression of the Smart Wearables in Healthcare industry covering different product Scope, Characterizations, Classifications, Objectives, and Participants in the industry chain structure. Smart Wearables in Healthcare Market (6 Forces Forecast 2021-2027) research report offers in-intensity insight of the Smart Wearables in Healthcare industry masking all vital parameters along with Marketing Channel, Direct Marketing, Indirect Marketing, Brand Strategy, Pricing Strategy, Market Positioning, Target Client, and Distributors/Traders List.

Smart Wearables in Healthcare Market report profiles major topmost players operating (Apple, Fitbit, Jawbone, Misfit, MyKronoz, Samsung, Philips, Huawei, Qualcomm Technologies, Inc, Adidas Group, Sony Corporation, Lifesense Group, Monica Healthcare, Garmin, Omron, Dragerwerk, Nokia Technologies, Polar Electro, World Global Network [Wor(I)D], Activeinsights, Vitalconnect, Xiaomi, Nuvo Group, TmG-BMC, Scanadu, Proteus, Empatica) in terms of analyses various attributes such as Company Profile, Product Specifications, Revenue, Gross, Gross Margin, Cost, Capacity, CAGR, Production Value and contact information.

Get FREE Sample PDF (including full TOC, Tables and Figures) of Smart Wearables in Healthcare Market@ https://www.researchmoz.us/enquiry.php?type=S&repid=2932305

Currently, Asia-Pacific is the largest market for the Smart Wearables in Healthcare having accounted for more than half of the global market size, by volume, in 2020. Among all the countries, China & India dominated the basic polymers market in 2020 in terms of volume, closely followed by Japan. High economic growth rate, rising demand for construction products made up of plastics, growing health awareness applications, improving standards of living and competitive manufacturing costs are the main factors leading to the growth of the market for Smart Wearables in Healthcare in this region.

Global Smart Wearables in Healthcare Market size will increase to xx Million US$ by 2027, from xx Million US$ in 2020, at a CAGR of xx% during the forecast period. In this study, 2020 has been considered as the base year and 2021 to 2027 as the forecast period to estimate the market size for Smart Wearables in Healthcare.

Purchase This Report Now By Availing Best Discount and Free Consultation : https://www.researchmoz.us/enquiry.php?type=D&repid=2932305

On the basis of product, this report displays the sales volume, revenue (Million USD), product price, market share and growth rate of each type, primarily split into-

  • Smart Wrist Wearables
  • Smart Patches
  • Smart Clothes
  • Smart Head / Neck Wearables
  • Smart Ear Wearables
  • Smart Eye Wearables
  • Other

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Smart Wearables in Healthcare Market  for each application, including-

  • Activity / Fitness Tracking (SMEs)
  • Remote Patient Monitoring & Diagnostics
  • Home Health Care
  • Others

Smart Wearables in Healthcare Market: Regional Analysis Includes:

  • Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)
  • Europe (Turkey, Germany, Russia UK, Italy, France, etc.)
  • North America (the United States, Mexico, and Canada.)
  • South America (Brazil etc.)
  • The Middle East and Africa (GCC Countries and Egypt.)

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert@ https://www.researchmoz.us/enquiry.php?type=E&repid=2932305

The Smart Wearables in Healthcare Market Report Helps Answer the Following Questions:
⦿   What is the current size of the overall Smart Wearables in Healthcare Market? How much will this market be worth from 2021 to 2027?
⦿  What are the market shares of the leading segments of the Smart Wearables in Healthcare Market in 2020?
⦿  What are the main segments within the overall Smart Wearables in Healthcare Market? How much will each of these segments be worth for the period 2017 to 2027?
⦿  What are the main drivers and restraints in the Smart Wearables in Healthcare Market?
⦿  What are the leading business manufactures? What are their revenue potentials to 2027?
⦿  What are the major deals happenings in the manufactures Smart Wearables in Healthcare Market?
⦿  Who are the leading manufactures and what are their activities, revenue, recent developments and prospects?
⦿  What are some of the most prominent Smart Wearables in Healthcare Market currently in development? What are their activities, platform technology and recent developments?

If you have any special requirements, please let us know and we will offer you the report as per your requirements.

Top Trending Reports:

https://www.marketwatch.com/press-release/youth-team-league-and-tournament-sports-market-gaining-revolution-in-eyes-of-global-exposure-2021-02-08?tesla=y
https://www.marketwatch.com/press-release/global-hemostasis-and-tissue-sealing-agents-market-to-reach-us-103-bn-by-2027-advanced-medical-solutions-group-plc-baxter-cohera-medical-inc-cryolife-inc-2021-02-08?tesla=y
https://www.marketwatch.com/press-release/e-cigarette-market-opportunity-for-business-development-by-region-2027-2021-02-08?tesla=y
https://www.marketwatch.com/press-release/top-trends-driving-the-future-of-healthcare-chatbots-market-latest-trade-trends-trades-supply-demand-prospects-by-2027-2021-02-08?tesla=y

Via EPR Network
More Healthcare press releases

URSAPHARM and CEBINA collaborating to repurpose the antihistamine drug azelastine hydrochloride as a potential anti-SARS-CoV-2 therapeutic

SAARBRÜCKEN / VIENNA, 17-Feb-2021 — /EPR HEALTHCARE NEWS/ — In the fight against the SARS-CoV-2 virus, a large number of pharmaceutical companies are looking for new approaches to combat the pandemic. In addition to vaccines, intensive research and development efforts around the world are focusing on identifying new anti-COVID therapeutics that includes re-evaluation of existing product portfolios with a view to re-purpose drugs that have antiviral properties.

With this goal in mind, URSAPHARM Arzneimittel GmbH, based in Saarbrücken, and the Vienna-based biotech company CEBINA GmbH (Central European Biotech Incubator and Accelerator) are collaborating to repurpose the antihistamine drug azelastine hydrochloride as a potential anti-SARS-CoV-2 therapeutic. Azelastine has been successfully used for many years in anti-allergic therapy.

Starting with a novel computational drug repurposing prediction method, developed and performed by Prof Dr Robert Konrat (University of Vienna), CEBINA selected already approved active substances for experimental testing in collaboration with Prof Dr. Ferenc Jakab (Virology National Laboratory, Szentágothai-Research-Center, University of Pécs, Hungary). This collaborative effort led to the identification of azelastine as a potent antiviral compound effective against SARS-CoV-2, a finding confirmed by now by several independent research groups. The potent anti-SARS-CoV-2 activity of azelastine was demonstrated in a reconstituted human nasal tissue model and was evident at a lower dose than present in commercially available nasal sprays [1].

A clinical trial has started on February 16th 2021 to verify whether the use of a nasal spray preparation containing azelastine can achieve a reduction in viral load in the the nasal cavity. The aim of the study is to show whether the anti-allergic medication Pollival® Nasal Spray, or a diluted version, can achieve a reduction in the viral load, therefore reducing transmission and positively influencing the course of the disease.

If positive results of the running clinical studies are demonstrated, URSAPHARM Arzneimittel GmbH and CEBINA GmbH believe this will be an important new approach to control viral spread and contain the current pandemic.

SOURCE: EuropaWire

Code18 Interactive Launches New Websites for Balmex and Balmex Adult

New York, NY, 2021-Jan-20 — /EPR HEALTHCARE NEWS/ — New York digital agency Code18 Interactive gives two health and wellness brands—Balmex Complete Protection and Balmex AdultAdvantage—custom websites that will provide peace of mind and relief for everyone from baby to grandpa. Both sites are fully responsive and built on the WordPress platform.

Code18 Interactive, a boutique digital agency based in New York City, announces the launch of new health and wellness websites for Balmex Complete Protectin and Balmex AdultAdvantage. Both are fully custom and fully responsive WordPress websites – https://balmex.com helps elevate and refresh a legacy brand while providing helpful diaper rash solutions and peace of mind for new parents, and https://balmexadult.com showcases over-the-counter relief for adults who experience skin irritation and chafing caused by incontinence or light bladder leakage. Both sites also feature e-commerce capabilities powered by WooCommerce, enabling the brands to offer Direct-to-Consumer sales for the first time.

The Balmex Complete Protection and Balmex AdultAdvantage brands are both part of the Randob Labs portfolio. Randob Labs is a private, family-held company that specializes in revitalizing and maintaining heritage brands on the OTC healthcare space. “Collaborating and working with Randob Labs has been an exciting adventure. Both Balmex and Balmex Adult provide big relief from common, irritating issues,” says Code18 Interactive founder Steve Pilon. “And providing relief and solutions to everyday problems is exactly what Randob Labs is all about. We’re thrilled to be a part of this process.”

As a well-established presence in the baby aisle, Balmex Complete Protection offers pediatrician-recommended diaper rash cream and multi-purpose healing ointment to help protect, soothe and heal baby’s delicate skin. “Many health and wellness websites only talk about what their product can do for consumers. However, Balmex is all about providing fast relief and reliable, proven solutions. Therefore, the website needed to clearly explain the causes of diaper rash and skin irritation, as well as provide simple steps parents can take to help prevent diaper rash in the first place,” says Pilon. “The brand’s willingness to go the extra mile for new parents is just one of the many reasons parents have been trusting Balmex for over 50 years.”

Clinically proven Balmex AdultAdvantage offers the same key benefits—a cream that protects, soothes and heals irritated and chafed skin—as its 50-year-old sibling brand. Available as a standalone skin relief cream or as part of an innovative on-the-go, 3-in-1 kit, Balmex AdultAdvantage helps older adults live life more comfortably. “For many older adults incontinence or bladder leakage controls their life, and unfortunately, many people just accept this fate,” says Pilon. “With the Balmex Adult website we really focused on awareness—awareness of this fantastic product, awareness of the benefits, and mostly, awareness that you can take back control of your life with Balmex AdultAdvantage.”

Code18 Interactive is a New York WordPress Agency that caters primarily to national consumer and media brands. The agency specializes in the design and development of enterprise-level WordPress and Magento 2 websites. They have the pleasure of working with many wonderful brands, including: GoGo squeeZ, Boursin Cheese, Public Radio International, The Laughing Cow, Grove Atlantic Publishing, C.O. Bigelow and many others.

For more information, please visit http://www.code18.com

Media contact:

Steve Pilon
Code18 Interactive
175 Varick Street, 8th Floor
New York, NY 10014 USA

Phone: 404-585-2725
https://code18.com

Via EPR Network
More Healthcare press releases

When Suffering From Endometriosis, The Natural Therapy Fuyan Pill Is A Useful Medicine For Pregnancy Plan Of Female Patients

Los Angeles, California, U.S.A., 2021-Jan-14 — /EPR HEALTHCARE NEWS/ — Reuters recently reported that British lawmakers called for urgent government action to support 1.5 million females with endometriosis — a debilitating condition that leads to absenteeism from school and work and can cause infertility. Female health experts said the lack of funding for research into the crippling illness — which affects one in ten females worldwide — showed how female health issues were often marginalized.

Female health issues should be paid attention to, while endometriosis is very harmful to the body health in females, which can cause persistent dysmenorrhea, menstrual disorders, urinary pain, low back pain, pelvic bleeding and other problems. If things go on like this, endometriosis will affect their learning efficiency, working performance, social life, relationships and mental health. In addition, they may have to face the problem of infertility.

In general, due to the ectopic endometrium attached to the abdominal cavity or ovarian surface, it can cause periodic shedding, congestion, edema, thus leading to the formation of chocolate cysts on the ovarian surface. The abnormal tissues can affect ovulation and then lead to infertility. Furthermore, the ectopic endometrium in the abdominal cavity will cause the viscera to stick together, causing the fallopian tubes to be blocked. In this case, the sperm and the egg cannot be combined into a fertilized egg in the fallopian tube, resulting in female infertility.

If a female friend has endometriosis and suffers from long-term infertility, doctors generally recommend her to receive a surgery to excise the diseased tissues. However, in some cases, due to the serious adhesions of the lesions, doctors are often unable to make a complete elimination, thus leading to a high recurrence rate of endometriosis.

On the flip side, doctors may adopt the therapeutic surgery, which involves the complete removal of both ovaries and the uterus. Actually, it’s relatively cruel to young and childless females, which not only directly deprives them of the reproductive rights, but also potentially triggers postmenopausal syndrome. Surgery can also induce secondary infections, leading to other inflammations such as pelvic inflammatory disease.

Obviously, surgery is a double-edged sword, which surely has some positive effects, but is not the best option, especially for females who want to raise children. A sound body is essential for a successful pregnancy. If you have to suffer from extra pain and risks due to the treatment method, it’s actually not worth trying. As a result, more and more patients with endometriosis are looking for safer solutions, and the natural therapy Fuyan Pill is a useful medicine for them.

The herbal medicine Fuyan Pill is developed by Wuhan Dr.Lee’s TCM Clinic, which has been granted the national patent in China. It can eliminate inflammations, kill various bacteria and viruses, clear away heat, remove blood stasis, relieve pain and so on. It’s made from more than 50 selected herbal ingredients, including radix bupleuri, poria, scutellaria baicalensis, gardenia, Chinese yam, talc, angelica sinensis, peach seed, safflower, licorice, etc.

The Fuyan Pill can effectively relieve the pain and discomfort caused by endometriosis, unblock the fallopian tubes, solve the adhesion issues, and provide a sound physiological environment for fertilization. In terms of traditional Chinese medicine, the cause of endometriosis is qi stagnation and blood stasis, and Fuyan Pill features the ability to promote blood circulation, remove blood stasis, eliminate inflammation and abnormal tissues. It can also regulate the menstruation and hormones, enhance the body immunity, and improve the female self-healing capacity.

As a natural therapy, Fuyan Pill has a strict formula and ratio in terms of the composition. Based on Dr. Lee’s more than 30 years of clinical experience, Fuyan Pill has been proved as an effective and safe oral product, which won’t lead to toxic side effects or unnecessary physiological pain and discomfort. For females who aspire to be a mother, Fuyan Pill can help them overcome endometriosis and get pregnant naturally.

We once cured a patient with endometriosis. Emily, a 28-year-old married female in America, was diagnosed with endometriosis and blocked fallopian tubes in 2017. After several attempts at treatment methods, including laparoscopic surgery and hormone therapy, her problems remained unresolved. Introduced by a friend last year, she contacted us and expressed her strong desire for childbirth through email, so we suggested her taking the Fuyan Pill.

After a month of treatment, Emily said that those painful symptoms had been improved so much that she didn’t hesitate to continue taking the pill for several months. Her illness has improved greatly and she is happy to tell us that she got pregnant two months ago. Now, she is actively preparing for the arrival of her baby.

As a natural plant medicine product, Fuyan Pill has a broad-spectrum bactericidal action with no side effects, which can not only treat endometriosis but also react well on pelvic inflammatory disease, endometritis, salpingitis, chlamydia infection, pelvic abscess, and other related problems. As a result, it can help females solve infertility caused by these gynecological diseases. We hope that females pay more attention to their body health. If you suffer from some problems mentioned above, Fuyan Pill is worth trying.

For more information about Fuyan Pill, please visits: https://global.fuyanpills.com/

About Dr. Lee Xiaoping:
Dr. Lee Xiaoping graduated from Hubei College of Traditional Chinese Medicine, China. She qualified as a herbalist 40 years ago and is a highly experienced medical professional. She specializes in the field of male and female reproductive and urinary system diseases. She has devoted 30 years to her clinic and worked on the formula of Fuyan Pill for years. The medicine has proven to be effective and cured thousands of people who suffered from endometriosis as well as its complications.

Media contact:

Lee Xiaoping
Herbalist
Wuhan Dr.Lee’s TCM Clinic
+86- 027-87105085
wuhandrli@gmail.com
herbalistlee@yahoo.com
wuhandrlee@hotmail.com

Via EPR Network
More Healthcare press releases